Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States
We evaluated the vaccine effectiveness (VE) of two doses of recombinant zoster vaccine (RZV) against herpes zoster (HZ) and postherpetic neuralgia (PHN) in Chinese adults at Kaiser Permanente Southern California (KPSC). Chinese KPSC members were identified based on self-reported ethnicity or self-re...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2327145 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850185121753202688 |
|---|---|
| author | Ana Florea Lina Sy Lei Qian Bradley Ackerson Yi Luo Jun Wu Yanjun Cheng Jennifer Ku Leticia Vega Daily Harpreet Takhar Jeannie Song Elizabeth Chmielewski-Yee O’Mareen Spence Harry Seifert Driss Oraichi Hung Fu Tseng |
| author_facet | Ana Florea Lina Sy Lei Qian Bradley Ackerson Yi Luo Jun Wu Yanjun Cheng Jennifer Ku Leticia Vega Daily Harpreet Takhar Jeannie Song Elizabeth Chmielewski-Yee O’Mareen Spence Harry Seifert Driss Oraichi Hung Fu Tseng |
| author_sort | Ana Florea |
| collection | DOAJ |
| description | We evaluated the vaccine effectiveness (VE) of two doses of recombinant zoster vaccine (RZV) against herpes zoster (HZ) and postherpetic neuralgia (PHN) in Chinese adults at Kaiser Permanente Southern California (KPSC). Chinese KPSC members were identified based on self-reported ethnicity or self-reported preferred spoken/written language. Those aged ≥50 years who received two doses of RZV 4 weeks to ≤ 6 months apart were matched 1:4 to RZV unvaccinated Chinese members and followed through June 2022; second doses were accrued 6/1/2018–12/31/2020. We estimated incidence and adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) comparing outcomes (HZ and PHN). Adjusted VE (%) was calculated as (1−aHR)×100. 3978 RZV vaccinated Chinese members were matched to 15,912 RZV unvaccinated Chinese members. The incidence per 1000 person-years (95% CI) of HZ in the vaccinated group was 1.5 (0.9–2.5) and 10.9 (9.8–12.1) in the unvaccinated group; aHR (95% CI) was 0.12 (0.07–0.21). Adjusted VE (95% CI) was 87.6% (78.9–92.7) against HZ. We identified 0 PHN cases in the vaccinated group and 19 in the unvaccinated group. Among Chinese adults aged ≥50 years, two doses of RZV provided substantial protection against HZ and PHN supporting the real-world effectiveness of the vaccine in this population. |
| format | Article |
| id | doaj-art-d183bd06668d4f9b85c20fcf2d7ac175 |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-d183bd06668d4f9b85c20fcf2d7ac1752025-08-20T02:16:49ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2327145Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United StatesAna Florea0Lina Sy1Lei Qian2Bradley Ackerson3Yi Luo4Jun Wu5Yanjun Cheng6Jennifer Ku7Leticia Vega Daily8Harpreet Takhar9Jeannie Song10Elizabeth Chmielewski-Yee11O’Mareen Spence12Harry Seifert13Driss Oraichi14Hung Fu Tseng15Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USADepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USADepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USADepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USADepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USADepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USADepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USADepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USADepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USADepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USADepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USADepartment of Epidemiology and Patient-Centered Outcomes, GSK, Rockville, MD, USADepartment of Epidemiology and Patient-Centered Outcomes, GSK, Rockville, MD, USADepartment of Clinical Safety and Pharmacovigilance, GSK, Rockville, MD, USADepartment of Real World Analytics, GSK, Rockville, MD, USADepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAWe evaluated the vaccine effectiveness (VE) of two doses of recombinant zoster vaccine (RZV) against herpes zoster (HZ) and postherpetic neuralgia (PHN) in Chinese adults at Kaiser Permanente Southern California (KPSC). Chinese KPSC members were identified based on self-reported ethnicity or self-reported preferred spoken/written language. Those aged ≥50 years who received two doses of RZV 4 weeks to ≤ 6 months apart were matched 1:4 to RZV unvaccinated Chinese members and followed through June 2022; second doses were accrued 6/1/2018–12/31/2020. We estimated incidence and adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) comparing outcomes (HZ and PHN). Adjusted VE (%) was calculated as (1−aHR)×100. 3978 RZV vaccinated Chinese members were matched to 15,912 RZV unvaccinated Chinese members. The incidence per 1000 person-years (95% CI) of HZ in the vaccinated group was 1.5 (0.9–2.5) and 10.9 (9.8–12.1) in the unvaccinated group; aHR (95% CI) was 0.12 (0.07–0.21). Adjusted VE (95% CI) was 87.6% (78.9–92.7) against HZ. We identified 0 PHN cases in the vaccinated group and 19 in the unvaccinated group. Among Chinese adults aged ≥50 years, two doses of RZV provided substantial protection against HZ and PHN supporting the real-world effectiveness of the vaccine in this population.https://www.tandfonline.com/doi/10.1080/21645515.2024.2327145Herpes zosterrecombinant zoster vaccineshinglesvaccinevaccine effectiveness |
| spellingShingle | Ana Florea Lina Sy Lei Qian Bradley Ackerson Yi Luo Jun Wu Yanjun Cheng Jennifer Ku Leticia Vega Daily Harpreet Takhar Jeannie Song Elizabeth Chmielewski-Yee O’Mareen Spence Harry Seifert Driss Oraichi Hung Fu Tseng Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States Human Vaccines & Immunotherapeutics Herpes zoster recombinant zoster vaccine shingles vaccine vaccine effectiveness |
| title | Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States |
| title_full | Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States |
| title_fullStr | Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States |
| title_full_unstemmed | Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States |
| title_short | Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States |
| title_sort | real world effectiveness of recombinant zoster vaccine in self identified chinese individuals aged ≥50 years in the united states |
| topic | Herpes zoster recombinant zoster vaccine shingles vaccine vaccine effectiveness |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2327145 |
| work_keys_str_mv | AT anaflorea realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT linasy realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT leiqian realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT bradleyackerson realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT yiluo realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT junwu realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT yanjuncheng realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT jenniferku realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT leticiavegadaily realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT harpreettakhar realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT jeanniesong realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT elizabethchmielewskiyee realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT omareenspence realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT harryseifert realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT drissoraichi realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates AT hungfutseng realworldeffectivenessofrecombinantzostervaccineinselfidentifiedchineseindividualsaged50yearsintheunitedstates |